日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A randomized study of apalutamide in Chinese patients with non-metastatic castration-resistant prostate cancer

一项针对中国非转移性去势抵抗性前列腺癌患者的阿帕鲁胺随机研究

期刊:iScience
影响因子:4.1
doi:10.1016/j.isci.2025.113166
Jiang, Shusuan; Tian, Ye; Guo, Hongqian; Guo, Jianming; Dong, Haiying; Luo, Hong; Xue, Wei; Xu, Tao; Li, Lei; Qiu, Mingxing; Xie, Liping; Lopez-Gitlitz, Angela; McCarthy, Sharon; Liu, Yanmei; Ma, Haocheng; Liang, Hongchuan; Li, Yanhui; Chen, Na; Ye, Dingwei
肿瘤
前列腺癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed Analysis

可切除早期非小细胞肺癌新辅助、围手术期和辅助化疗免疫疗法的III期临床试验：综合综述和详细分析

期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2025.100866
Lee, Jay M; Brunelli, Alessandro; Cummings, Amy L; Felip, Enriqueta; Shu, Catherine A; Solomon, Benjamin J; Tsuboi, Masahiro; Wakelee, Heather; Saqi, Anjali; Wu, Yi-Long; Li, Pao-Chen; Gitlitz, Barbara J
肺癌
肿瘤
肿瘤免疫
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)

针对不应接受铂类化疗的非小细胞肺癌患者，比较阿特珠单抗与单药化疗的疗效（IPSOS 研究）的简明语言摘要

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2025.2500915
Lee, Siow Ming; Schulz, Christian; Baird, Anne-Marie; Prabhash, Kumar; Kowalski, Dariusz; Szczesna, Aleksandra; Han, Baohui; Rittmeyer, Achim; Talbot, Toby; Vicente, David; Califano, Raffaele; Cortinovis, Diego; Le, Anh Tuan; Huang, Dingzhi; Liu, Geoffrey; Cappuzzo, Federico; Reyes Contreras, Jessica; Reck, Martin; Palmero, Ramon; Perez Mak, Milena; Hu, Youyou; Morris, Stefanie; Kaul, Monika; Corey-Lisle, Patricia; Gitlitz, Barbara; Peters, Solange
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer

MAGNITUDE 研究结果的简明语言摘要，该研究评估了尼拉帕尼和醋酸阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌患者的疗效和安全性。

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2025.2470106
Chi, Kim N; Rathkopf, Dana; Smith, Matthew R; Efstathiou, Eleni; Attard, Gerhardt; Olmos, David; Lee, Ji Youl; Small, Eric J; Pereira de Santana Gomes, Andrea J; Roubaud, Guilhem; Saad, Marniza; Zurawski, Bogdan; Sakalo, Valerii; Mason, Gary E; Francis, Peter; Wang, George; Wu, Daphne; Diorio, Brooke; Lopez-Gitlitz, Angela; Sandhu, Shahneen
MAG
肿瘤
前列腺癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Being a Surrogate Partner: The Challenges of Fragile Boundaries

成为代孕伴侣：脆弱边界带来的挑战

期刊:Archives of Sexual Behavior
影响因子:2.9
doi:10.1007/s10508-024-02821-9
Oreg, Ayelet; Avlagon, Elad; Gitlitz, Tamar
发表日期：2024
文献求助 收藏

Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma

帕博利珠单抗联合可溶性EphB4-白蛋白治疗HPV阴性EphrinB2阳性头颈部鳞状细胞癌的疗效得到改善

期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.28605
Jackovich, Alexandra; Gitlitz, Barbara J; Tiu-Lim, Justin Wayne Wong; Duddalwar, Vinay; King, Kevin George; El-Khoueiry, Anthony B; Thomas, Jacob Stephen; Tsao-Wei, Denice; Quinn, David I; Gill, Parkash S; Nieva, Jorge J
细胞生物学
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

尼拉帕尼和醋酸阿比特龙治疗转移性去势抵抗性前列腺癌

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.22.01649
Chi, Kim N; Rathkopf, Dana; Smith, Matthew R; Efstathiou, Eleni; Attard, Gerhardt; Olmos, David; Lee, Ji Youl; Small, Eric J; Pereira de Santana Gomes, Andrea J; Roubaud, Guilhem; Saad, Marniza; Zurawski, Bogdan; Sakalo, Valerii; Mason, Gary E; Francis, Peter; Wang, George; Wu, Daphne; Diorio, Brooke; Lopez-Gitlitz, Angela; Sandhu, Shahneen
肿瘤
前列腺癌
肿瘤免疫
发表日期：2023
文献求助 收藏

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial

SP263 和 22C3 免疫组化 PD-L1 检测方法在非小细胞肺癌辅助治疗阿特珠单抗临床疗效评估中的比较：来自随机 III 期 IMpower010 试验的结果

期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2023-007047
Zhou, Caicun; Srivastava, Minu K; Xu, Hao; Felip, Enriqueta; Wakelee, Heather; Altorki, Nasser; Reck, Martin; Liersch, Rüdiger; Kryzhanivska, Anna; Oizumi, Satoshi; Tanaka, Hiroshi; Hamm, John; McCune, Steven L; Bennett, Elizabeth; Gitlitz, Barbara; McNally, Virginia; Ballinger, Marcus; McCleland, Mark; Zou, Wei; Das Thakur, Meghna; Novello, Silvia
肺癌
肿瘤
IHC
肿瘤免疫
PD-L1
细胞生物学
免疫/内分泌
发表日期：2023
文献求助 收藏

Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects

GALAHAD研究中与健康相关的生活质量：一项针对转移性去势抵抗性前列腺癌伴DNA修复基因缺陷患者的尼拉帕尼多中心、开放标签II期研究

期刊:
影响因子:
doi:10.18553/jmcp.2023.29.7.758
Smith, Matthew R; Sandhu, Shahneen; George, Daniel J; Chi, Kim Nguyen; Saad, Fred; Thiery-Vuillemin, Antoine; Stàhl, Olaf; Olmos, David; Danila, Daniel C; Gafanov, Rustem; Castro, Elena; Moon, Helen; Joshua, Anthony M; Mason, Gary E; Espina, Byron M; Liu, Yan; Lopez-Gitlitz, Angela; Francis, Peter; Bevans, Katherine B; Fizazi, Karim
肿瘤
前列腺癌
肿瘤免疫
发表日期：2023
文献求助 收藏

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

尼拉帕尼治疗伴有DNA修复基因缺陷的转移性去势抵抗性前列腺癌患者（GALAHAD）：一项多中心、开放标签的II期试验

期刊:Lancet Oncology
影响因子:35.9
doi:10.1016/S1470-2045(21)00757-9
Smith, Matthew R; Scher, Howard I; Sandhu, Shahneen; Efstathiou, Eleni; Lara, Primo N Jr; Yu, Evan Y; George, Daniel J; Chi, Kim N; Saad, Fred; Ståhl, Olof; Olmos, David; Danila, Daniel C; Mason, Gary E; Espina, Byron M; Zhao, Xin; Urtishak, Karen A; Francis, Peter; Lopez-Gitlitz, Angela; Fizazi, Karim
肿瘤
前列腺癌
肿瘤免疫
发表日期：2022
文献求助 收藏